AN2 Therapeutics Stock Forecast

Stock Price Forecast

The 2 analysts with 12-month price forecasts for AN2 Therapeutics stock have an average target of $9.00, which predicts a 85.95% increase from the current stock price of 4.84.

Price Target: $9.00 (+85.95%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$9.00	$9.00	$9.00	$9.00
Change	+85.95%	+85.95%	+85.95%	+85.95%

Analyst Ratings

The average analyst rating for AN2 Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Nov '25	Jan '26	Mar '26	May '26	Jun '26	Jul '26
Strong Buy	0	0	0	1	1	2
Buy	0	0	0	0	0	0
Hold	1	1	1	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	1	1	1	1	1	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Bradley Canino Guggenheim	Guggenheim	Buy Initiates $9	Buy	Initiates	$9	+85.95%	Jul 20, 2026
Joseph Schwartz Leerink Partners	Leerink Partners	Buy Upgrades $9	Buy	Upgrades	$9	+85.95%	May 14, 2026

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

n/a

EPS This Year

-1.05

from -1.16

EPS Next Year

-0.93

from -1.05

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-	-
Operating Income	-21.57M	-42.26M	-69.64M	-54.55M	-38.11M	-47.40M
Net Income	-21.54M	-40.96M	-64.73M	-51.32M	-35.17M	-43.00M
EPS	-	-	-	-	-1.16	-1.05
Free Cash Flow	-11.96M	-19.30M	-28.85M	-29.00M	-18.38M	-115.00M
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.96
Avg	-1.05
Low	-1.13

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-